{"id":"matching-placebo-injections","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Matching placebo injections are used to ensure that the new drug being tested is the actual cause of any observed effects, rather than other factors. This is done by creating a control group that receives a placebo that is identical to the new drug in every way except for the active ingredient.","oneSentence":"Matching placebo injections are used to compare the efficacy of a new drug to a placebo.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:16.283Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Comparing the efficacy of a new drug to a placebo"}]},"trialDetails":[{"nctId":"NCT06972446","phase":"PHASE2","title":"A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-06-20","conditions":"Rheumatoid Arthritis","enrollment":180},{"nctId":"NCT07496450","phase":"PHASE3","title":"A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2026-03-23","conditions":"Influenza","enrollment":4000},{"nctId":"NCT06196879","phase":"PHASE2","title":"A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)","status":"COMPLETED","sponsor":"Upstream Bio Inc.","startDate":"2024-02-27","conditions":"Severe Asthma","enrollment":479},{"nctId":"NCT07037771","phase":"PHASE3","title":"A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)","status":"RECRUITING","sponsor":"Arrowhead Pharmaceuticals","startDate":"2025-06-17","conditions":"Homozygous Familial Hypercholesterolemia","enrollment":60},{"nctId":"NCT05531565","phase":"PHASE2, PHASE3","title":"A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus","status":"RECRUITING","sponsor":"Biogen","startDate":"2022-09-13","conditions":"Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus","enrollment":450},{"nctId":"NCT06727552","phase":"PHASE2","title":"A Study of Barzolvolimab in Patients With Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celldex Therapeutics","startDate":"2024-12-18","conditions":"Atopic Dermatitis","enrollment":131},{"nctId":"NCT06963827","phase":"PHASE3","title":"A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-07-15","conditions":"Kidney Disease","enrollment":347},{"nctId":"NCT06954987","phase":"PHASE2","title":"Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-17","conditions":"Acute Myeloid Leukemia","enrollment":244},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT05318976","phase":"PHASE2","title":"A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation","status":"COMPLETED","sponsor":"Inmune Bio, Inc.","startDate":"2022-02-28","conditions":"Alzheimer Disease, Dementia, Brain Diseases","enrollment":208},{"nctId":"NCT07363694","phase":"PHASE2, PHASE3","title":"A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease","status":"RECRUITING","sponsor":"Pfizer","startDate":"2026-02-11","conditions":"Moderate to Severe Chronic Obstructive Pulmonary Disease","enrollment":1156},{"nctId":"NCT05152173","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability, of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2021-11-29","conditions":"Plantar Fibromatosis","enrollment":176},{"nctId":"NCT07284901","phase":"PHASE3","title":"Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes","status":"RECRUITING","sponsor":"Kailera","startDate":"2026-01-12","conditions":"Obesity With Diabetes, Overweight With Diabetes","enrollment":1700},{"nctId":"NCT06033196","phase":"PHASE2","title":"Tocilizumab in Lung Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-02-13","conditions":"Lung Transplant","enrollment":350},{"nctId":"NCT07277660","phase":"PHASE2","title":"A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis","status":"RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2025-12-29","conditions":"Atopic Dermatitis","enrollment":160},{"nctId":"NCT07266402","phase":"PHASE3","title":"A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)","status":"RECRUITING","sponsor":"Celldex Therapeutics","startDate":"2026-01-15","conditions":"Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria","enrollment":240},{"nctId":"NCT04297683","phase":"PHASE2, PHASE3","title":"HEALEY ALS Platform Trial - Master Protocol","status":"RECRUITING","sponsor":"Merit E. Cudkowicz, MD","startDate":"2020-06-14","conditions":"Amyotrophic Lateral Sclerosis","enrollment":1500},{"nctId":"NCT07446998","phase":"PHASE2","title":"Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss","status":"RECRUITING","sponsor":"Veru Inc.","startDate":"2026-03","conditions":"Obesity & Overweight, Mobility Disability, HOMA-IR","enrollment":200},{"nctId":"NCT07498751","phase":"PHASE1","title":"Phase I PK and Safety Study of Ondansetron Inhalation Powder","status":"COMPLETED","sponsor":"Luxena Pharmaceuticals, Inc.","startDate":"2025-03-13","conditions":"Postoperative Nausea and Vomiting","enrollment":24},{"nctId":"NCT06445023","phase":"PHASE3","title":"A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celldex Therapeutics","startDate":"2024-07-11","conditions":"Chronic Spontaneous Urticaria","enrollment":963},{"nctId":"NCT06603077","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa","status":"ACTIVE_NOT_RECRUITING","sponsor":"Avalo Therapeutics, Inc.","startDate":"2024-09-16","conditions":"Hidradenitis Suppurativa","enrollment":250},{"nctId":"NCT06455202","phase":"PHASE3","title":"A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celldex Therapeutics","startDate":"2024-07-19","conditions":"Chronic Spontaneous Urticaria","enrollment":976},{"nctId":"NCT07485764","phase":"PHASE4","title":"Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-06","conditions":"Psoriasis, Plaque Psoriasis, Moderate-to-severe Plaque Psoriasis","enrollment":186},{"nctId":"NCT07489599","phase":"PHASE1","title":"A Study of QLH2405 in Healthy Participants and Participants With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-03","conditions":"Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)","enrollment":68},{"nctId":"NCT07221474","phase":"PHASE2","title":"A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-12","conditions":"Squamous Non-small Cell Lung Cancer","enrollment":180},{"nctId":"NCT06339008","phase":"PHASE3","title":"A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-04-26","conditions":"Perennial Allergic Rhinitis (PAR)","enrollment":450},{"nctId":"NCT07300085","phase":"PHASE1","title":"A Trial to Evaluate the Effect of CD388 on the Immunogenicity of Fluzone® HD Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cidara Therapeutics Inc.","startDate":"2025-11-08","conditions":"Healthy Participants","enrollment":100},{"nctId":"NCT06077760","phase":"PHASE3","title":"A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-06","conditions":"Non-small Cell Lung Cancer","enrollment":868},{"nctId":"NCT06914609","phase":"PHASE3","title":"REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome","status":"RECRUITING","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2025-06-10","conditions":"Angelman Syndrome","enrollment":158},{"nctId":"NCT06623422","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-10-21","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":680},{"nctId":"NCT07276581","phase":"PHASE2","title":"A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-15","conditions":"Rheumatoid Arthritis","enrollment":320},{"nctId":"NCT06153966","phase":"PHASE1, PHASE2","title":"PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717","status":"RECRUITING","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2024-01-04","conditions":"Prion Disease","enrollment":76},{"nctId":"NCT07225569","phase":"PHASE2","title":"A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-12-29","conditions":"Hidradenitis Suppurativa","enrollment":144},{"nctId":"NCT04720534","phase":"PHASE2","title":"Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia","status":"COMPLETED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2021-05-31","conditions":"Severe Hypertriglyceridemia","enrollment":229},{"nctId":"NCT06989437","phase":"PHASE2, PHASE3","title":"A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-10-03","conditions":"Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":982},{"nctId":"NCT06209177","phase":"PHASE1","title":"Study of ARO-CFB in Adult Healthy Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arrowhead Pharmaceuticals","startDate":"2024-04-05","conditions":"IgA Nephropathy","enrollment":49},{"nctId":"NCT07088068","phase":"PHASE3","title":"A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-08-06","conditions":"Type 1 Diabetes Mellitus","enrollment":723},{"nctId":"NCT06662539","phase":"PHASE2","title":"Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities","status":"COMPLETED","sponsor":"Zealand Pharma","startDate":"2024-12-09","conditions":"Obesity","enrollment":493},{"nctId":"NCT07190222","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-09-17","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":942},{"nctId":"NCT05075824","phase":"PHASE2","title":"A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-03-09","conditions":"Sickle Cell Disease","enrollment":90},{"nctId":"NCT05992935","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-08-25","conditions":"Norovirus Acute Gastroenteritis","enrollment":1405},{"nctId":"NCT07487545","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SSS67 in Healthy Adult Participants Via Single Intravenous Infusion","status":"NOT_YET_RECRUITING","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","startDate":"2026-03-31","conditions":"Healthy","enrollment":52},{"nctId":"NCT07190209","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-09-16","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":942},{"nctId":"NCT07487376","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of IBIO-600 in Overweight or Obese Adults","status":"NOT_YET_RECRUITING","sponsor":"iBio, Inc.","startDate":"2026-04","conditions":"Overweight , Obesity","enrollment":32},{"nctId":"NCT05352919","phase":"PHASE3","title":"An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus","status":"ENROLLING_BY_INVITATION","sponsor":"Biogen","startDate":"2022-06-10","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":864},{"nctId":"NCT06468228","phase":"PHASE3","title":"A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-06-27","conditions":"Hidradenitis Suppurativa","enrollment":1280},{"nctId":"NCT07281495","phase":"PHASE2","title":"Taldefgrobep Alfa in Adults With Overweight and Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biohaven Therapeutics Ltd.","startDate":"2025-11-24","conditions":"Obesity, Overweight","enrollment":150},{"nctId":"NCT05097287","phase":"PHASE4","title":"Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2021-12-16","conditions":"Asthma","enrollment":1324},{"nctId":"NCT06191315","phase":"PHASE3","title":"Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-01-03","conditions":"Wheezing, Asthma","enrollment":90},{"nctId":"NCT06229483","phase":"PHASE3","title":"The Effects of Intraoperative Tranexamic Acid on Perioperative Bleeding In Craniotomies","status":"RECRUITING","sponsor":"Stephen Lownie","startDate":"2024-04-03","conditions":"Brain Tumor, Bleeding","enrollment":102},{"nctId":"NCT06632457","phase":"PHASE3","title":"LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2024-11-07","conditions":"Metabolic Dysfunction Associated Steatohepatitis","enrollment":1590},{"nctId":"NCT06282588","phase":"PHASE2, PHASE3","title":"Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers","status":"RECRUITING","sponsor":"Cancer Research Antwerp","startDate":"2023-12-13","conditions":"Prostate Cancer","enrollment":493},{"nctId":"NCT06589986","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2024-09-17","conditions":"Moderately to Severely Active Ulcerative Colitis","enrollment":400},{"nctId":"NCT07481734","phase":"PHASE2","title":"Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)","status":"RECRUITING","sponsor":"Hudson Biotech","startDate":"2026-02-02","conditions":"Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis, Hepatic Steatosis","enrollment":120},{"nctId":"NCT07227948","phase":"PHASE2","title":"Repurposing Semaglutide for the Treatment of Cocaine Use Disorder","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2026-01-15","conditions":"Cocaine Use Disorder","enrollment":75},{"nctId":"NCT06455449","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-06-20","conditions":"Polymyositis, Dermatomyositis","enrollment":240},{"nctId":"NCT06995820","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-06-06","conditions":"Healthy","enrollment":136},{"nctId":"NCT07161999","phase":"PHASE2","title":"Study of COYA 302 for the Treatment of ALS","status":"RECRUITING","sponsor":"Coya Therapeutics","startDate":"2025-10-01","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":120},{"nctId":"NCT05248386","phase":"PHASE3","title":"Efficacy and Safety of RTX-GRT7039 in Adult Subjects With Knee Osteoarthritis","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2022-08-26","conditions":"Osteoarthritis","enrollment":469},{"nctId":"NCT04379635","phase":"PHASE3","title":"Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2020-05-29","conditions":"Non Small Cell Lung Cancer","enrollment":453},{"nctId":"NCT04661540","phase":"PHASE2","title":"A Study of Auxora in Patients With Critical COVID-19 Pneumonia","status":"TERMINATED","sponsor":"CalciMedica, Inc.","startDate":"2021-03-02","conditions":"Pneumonia","enrollment":10},{"nctId":"NCT07479862","phase":"PHASE1","title":"A Study of SA030 Injection in Overweight or Obese Participants","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Siran Biotechnology Co.,Ltd.","startDate":"2026-04-16","conditions":"Obese, Overweight","enrollment":40},{"nctId":"NCT05492500","phase":"PHASE2","title":"A Study of Ponsegromab in People With Heart Failure","status":"TERMINATED","sponsor":"Pfizer","startDate":"2022-09-26","conditions":"Heart Failure","enrollment":455},{"nctId":"NCT06226805","phase":"PHASE2","title":"Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)","status":"RECRUITING","sponsor":"Basking Biosciences, Inc.","startDate":"2024-07-31","conditions":"Acute Ischemic Stroke","enrollment":228},{"nctId":"NCT05449132","phase":"PHASE3","title":"Comparison of a Single RTX-GRT7039 and Placebo Intra-articular Injection for Pain Associated With Osteoarthritis of the Knee","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2022-09-26","conditions":"Osteoarthritis","enrollment":466},{"nctId":"NCT06577766","phase":"PHASE1","title":"A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2024-09-03","conditions":"Obesity, Overweight","enrollment":63},{"nctId":"NCT05693935","phase":"PHASE3","title":"A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D LLC","startDate":"2023-01-24","conditions":"Schizophrenia","enrollment":675},{"nctId":"NCT07476586","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics of GenSci161 in Healthy Adult Participants","status":"NOT_YET_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2026-04-23","conditions":"Healthy Volunteers","enrollment":44},{"nctId":"NCT06819891","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-05-12","conditions":"Moderately to Severely Active Crohns Disease","enrollment":425},{"nctId":"NCT04119050","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-08-15","conditions":"Warm Autoimmune Hemolytic Anemia","enrollment":118},{"nctId":"NCT05528510","phase":"PHASE3","title":"A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-09-13","conditions":"Colitis, Ulcerative","enrollment":418},{"nctId":"NCT07327931","phase":"NA","title":"PENG Block Variants With Dexamethasone and Dexmedetomidine in Older Adults","status":"RECRUITING","sponsor":"Poznan University of Medical Sciences","startDate":"2026-02-13","conditions":"Hip Osteoarthritis, Hip Pain Chronic","enrollment":120},{"nctId":"NCT05739383","phase":"PHASE3","title":"A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-03-09","conditions":"Primary Prevention of Atherosclerotic Cardiovascular Disease","enrollment":14078},{"nctId":"NCT05683457","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-04-05","conditions":"Cytomegalovirus Infection","enrollment":224},{"nctId":"NCT05811351","phase":"PHASE2","title":"A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-03-06","conditions":"Geographic Atrophy","enrollment":305},{"nctId":"NCT06812988","phase":"PHASE2","title":"Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-02-28","conditions":"Type 1 Diabetes Mellitus","enrollment":84},{"nctId":"NCT05115110","phase":"PHASE2, PHASE3","title":"A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-06-02","conditions":"Spinal Muscular Atrophy (SMA)","enrollment":259},{"nctId":"NCT07390747","phase":"PHASE1","title":"A Trial of SHR-2173 in Healthy Volunteers","status":"RECRUITING","sponsor":"Atridia Pty Ltd.","startDate":"2026-03-06","conditions":"Immunology","enrollment":18},{"nctId":"NCT05797610","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-08-08","conditions":"Primary IgA Nephropathy","enrollment":428},{"nctId":"NCT05271409","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-08-30","conditions":"Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)","enrollment":152},{"nctId":"NCT05925803","phase":"PHASE3","title":"Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-08","conditions":"Systemic Sclerosis, Scleroderma","enrollment":314},{"nctId":"NCT07284979","phase":"PHASE3","title":"Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes","status":"RECRUITING","sponsor":"Kailera","startDate":"2025-12-30","conditions":"Obesity","enrollment":1200},{"nctId":"NCT07090655","phase":"EARLY_PHASE1","title":"A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections in Normal Healthy Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Climb Bio, Inc.","startDate":"2025-08-11","conditions":"Healthy Volunteers","enrollment":38},{"nctId":"NCT07469800","phase":"PHASE3","title":"Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity","status":"NOT_YET_RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2026-04-01","conditions":"Overweight, Obesity, Hypertensive","enrollment":336},{"nctId":"NCT04882098","phase":"PHASE3","title":"A Study of Guselkumab in Participants With Active Psoriatic Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-06-17","conditions":"Arthritis, Psoriatic","enrollment":1054},{"nctId":"NCT04929210","phase":"PHASE4","title":"A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-08-30","conditions":"Arthritis, Psoriatic","enrollment":411},{"nctId":"NCT05856526","phase":"PHASE2, PHASE3","title":"A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2023-06-12","conditions":"Netherton Syndrome","enrollment":43},{"nctId":"NCT07467447","phase":"PHASE2","title":"Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight","status":"RECRUITING","sponsor":"Hudson Biotech","startDate":"2026-02-15","conditions":"Obesity","enrollment":300},{"nctId":"NCT07137585","phase":"PHASE1","title":"A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants With Type 2 Diabetes Mellitus (T2DM) and Overweight or Obesity","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-09-30","conditions":"Type 2 Diabetes Mellitus, Obesity, Overweight","enrollment":30},{"nctId":"NCT04936308","phase":"PHASE3","title":"Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-09-28","conditions":"Arthritis, Psoriatic","enrollment":453},{"nctId":"NCT05649137","phase":"PHASE3","title":"A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-01-04","conditions":"Obesity, Diabetes Mellitus, Type 2","enrollment":512},{"nctId":"NCT06717698","phase":"PHASE2","title":"A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2024-12-02","conditions":"Chronic Kidney Disease","enrollment":465},{"nctId":"NCT03953300","phase":"PHASE4","title":"Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-10-08","conditions":"Asthma","enrollment":75},{"nctId":"NCT07170917","phase":"PHASE2","title":"Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-11-06","conditions":"Hidradenitis Suppurativa","enrollment":208},{"nctId":"NCT06470048","phase":"PHASE2","title":"A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-10-09","conditions":"Diffuse Cutaneous Systemic Sclerosis","enrollment":200},{"nctId":"NCT06015737","phase":"PHASE3","title":"A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-06-29","conditions":"Cutaneous Lupus Erythematosus","enrollment":302},{"nctId":"NCT06868212","phase":"PHASE3","title":"A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-07-11","conditions":"Chronic Spontaneous Urticaria (CSU)","enrollment":400},{"nctId":"NCT04314531","phase":"PHASE3","title":"Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2020-07-01","conditions":"Active Psoriatic Arthritis","enrollment":296},{"nctId":"NCT07167966","phase":"PHASE2","title":"Alzheimer's Tau Platform: Regimen A - AADvac1","status":"NOT_YET_RECRUITING","sponsor":"Paul S. Aisen","startDate":"2026-06-30","conditions":"Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease","enrollment":375},{"nctId":"NCT06834347","phase":"PHASE3","title":"A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-02-12","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":210}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"matching placebo injections","genericName":"matching placebo injections","companyName":"Sun Pharmaceutical Industries Limited","companyId":"sun-pharmaceutical-industries-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Matching placebo injections are used to compare the efficacy of a new drug to a placebo. Used for Comparing the efficacy of a new drug to a placebo.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}